TY - JOUR
T1 - Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome
AU - Sacchi, A.
AU - Grassi, G.
AU - Bordoni, V.
AU - Lorenzini, P.
AU - Cimini, E.
AU - Casetti, R.
AU - Tartaglia, E.
AU - Marchioni, L.
AU - Petrosillo, N.
AU - Palmieri, F.
AU - D'Offizi, G.
AU - Notari, S.
AU - Tempestilli, M.
AU - Capobianchi, M. R.
AU - Nicastri, E.
AU - Maeurer, M.
AU - Zumla, A.
AU - Locatelli, Franco
AU - Antinori, A.
AU - Ippolito, G.
AU - Agrati, C.
PY - 2020
Y1 - 2020
N2 - The immunological mechanisms underlying the clinical presentation of SARS-CoV-2 infection and those influencing the disease outcome remain to be defined. Myeloid-derived suppressor cells (MDSC) have been described to be highly increased during COVID-19, however, their role remains elusive. We performed an in depth analysis of MDSC in 128 SARS-CoV-2 infected patients. Polymorphonuclear (PMN)-MDSC expanded during COVID-19, in particular in patients who required intensive care treatments, and correlated with IL-1β, IL-6, IL-8, and TNF-α plasma levels. PMN-MDSC inhibited T-cells IFN-γ production upon SARS-CoV-2 peptides stimulation, through TGF-β- and iNOS-mediated mechanisms, possibly contrasting virus elimination. Accordingly, a multivariate regression analysis found a strong association between PMN-MDSC percentage and fatal outcome of the disease. The PMN-MDSC frequency was higher in non-survivors than survivors at the admission time, followed by a decreasing trend. Interestingly, this trend was associated with IL-6 increase in non-survivors but not in survivors. In conclusion, this study indicates PMN-MDSC as a novel factor in the pathogenesis of SARS-CoV2 infection, and open up to new therapeutic options.
AB - The immunological mechanisms underlying the clinical presentation of SARS-CoV-2 infection and those influencing the disease outcome remain to be defined. Myeloid-derived suppressor cells (MDSC) have been described to be highly increased during COVID-19, however, their role remains elusive. We performed an in depth analysis of MDSC in 128 SARS-CoV-2 infected patients. Polymorphonuclear (PMN)-MDSC expanded during COVID-19, in particular in patients who required intensive care treatments, and correlated with IL-1β, IL-6, IL-8, and TNF-α plasma levels. PMN-MDSC inhibited T-cells IFN-γ production upon SARS-CoV-2 peptides stimulation, through TGF-β- and iNOS-mediated mechanisms, possibly contrasting virus elimination. Accordingly, a multivariate regression analysis found a strong association between PMN-MDSC percentage and fatal outcome of the disease. The PMN-MDSC frequency was higher in non-survivors than survivors at the admission time, followed by a decreasing trend. Interestingly, this trend was associated with IL-6 increase in non-survivors but not in survivors. In conclusion, this study indicates PMN-MDSC as a novel factor in the pathogenesis of SARS-CoV2 infection, and open up to new therapeutic options.
KW - SARS-COV-2
KW - SARS-COV-2
UR - https://publicatt.unicatt.it/handle/10807/228781
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85094126690&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85094126690&origin=inward
U2 - 10.1038/s41419-020-03125-1
DO - 10.1038/s41419-020-03125-1
M3 - Article
SN - 2041-4889
VL - 11
SP - 1
EP - 9
JO - CELL DEATH & DISEASE
JF - CELL DEATH & DISEASE
IS - 10
ER -